Toggle navigation
Home
Search
Services
Blog
Contact
About
No. 73 a Phase Iia Cancer Prevention Trial of the Ppar/ Agonist Piogli-261015000
University of Minnesota Twin Cities, Minneapolis, MN, United States
Search grants from University of Minnesota Twin Cities
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Publications
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Intestinal Microbiome Fructan Metabolism and Symptom Generation in Childhood IBS
Office of the Scientific Director
BCAP/PI3K regulation of innate immunity to Listeria monocytogenes
UT Gastroenterology / Hepatology Research Training Program
Breast Cancer in Women Under the Age of 45 Field Centers
Recently added grants:
Core A: Administration
The role of neuroactive steroids in stress, drug craving and drug use in cocaine use disorders
Core B: Gene Modulation with RNAi and CRISPER
Digital treatments for opioids and other substance use disorders (DIGITS) in primary care: A hybrid type-III implementation trial
Sleep regulates drug relapse and addiction
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
Division of Cancer Prevention And Control (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CN015000-001
Application #
6994812
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2004
Total Cost
Indirect Cost
Institution
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Related projects
NIH 2006
N01 CN
No. 73 a Phase Iia Cancer Prevention Trial of the Ppar/ Agonist Piogli-261015000
/ University of Minnesota Twin Cities
NIH 2004
N01 CN
No. 73 a Phase Iia Cancer Prevention Trial of the Ppar/ Agonist Piogli-261015000
/ University of Minnesota Twin Cities
Publications
Rosas, R R; Cole, K A; Darrah, L et al.
(2012)
A comparison of screening methods in two early phase oral leukoplakia clinical trials.
Oral Dis 18:720-3
Comments
Be the first to comment on this grant